News Search Results
Aug 26, 2025, 04:00 ET High-Precision Base Editing Clinical Treatment for Sickle Cell Disease -- CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient
Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the
More news about: CorrectSequence Therapeutics
Aug 26, 2025, 02:00 ET High-Precision Base Editing Clinical Treatment for Sickle Cell Disease -- CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient
Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the
More news about: CorrectSequence Therapeutics
Aug 26, 2025, 01:36 ET CAPR Stockholders with Large Losses Should Contact Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit
securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating
More news about: Robbins LLP
Aug 25, 2025, 15:54 ET Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution
the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the "Transaction"), the Nasdaq Stock Market LLC ("Nasdaq")
More news about: ESSA Pharma Inc.
Aug 25, 2025, 13:04 ET Human Longevity Taps Alamar Biosciences to Power Proteomic Innovation in Longevity Research
AI, multi-omics, and next-generation diagnostics. About Human Longevity, Inc. Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, AI, and multimodal diagnostics to extend human healthspan. Through its flagship Executive Health
More news about: Human Longevity, Inc.
Aug 25, 2025, 13:03 ET Future Origins Receives National Award for Green Chemistry from ACS
Award in London on November 13, 2025. Future Origins was founded by industrial biotechnology leader Geno, in partnership with Unilever, Kao, and L'Oréal. Geno has been awarded the Presidential Green Chemistry Challenge Award four times previously
More news about: Future Origins
Aug 25, 2025, 11:38 ET Thryv Therapeutics to Present at the 2025 European Society of Cardiology Congress in Madrid, Spain
MONTREAL, Aug. 25, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company, today announced that Dr. Saumya Das will present compelling new preclinical results on its lead compound,
More news about: Thryv Therapeutics Inc.
Aug 25, 2025, 11:16 ET Prebiotic Fiber Market to Reach USD 2.3 Billion by 2031, Fueled by Gut Health & Functional Foods Boom | Valuates Reports
BeneoTereosSensusCosucraThe Tierra GroupTinjoy HealthcareChengdu iMOS BiotechnologyBiomartLallemandOrffaFUBON / Angel YeastSensientBiofeedGuangdong VTR
More news about: Valuates Reports
Aug 25, 2025, 10:45 ET Patent Search Software Market is expected to generate a revenue of USD 2.28 Billion by 2031, Globally, at 12.32% CAGR: Verified Market Research®
Global Patent Database Market Size By Patent Type (Utility Patents, Design Patents), By Industry Application (Information Technology, Biotechnology), By Patent Stage (Pending Patents, Granted Patents), By Ownership Structure (Individual Inventors, Small and Medium Enterprises), By Geography,
More news about: Verified Market Research
Aug 25, 2025, 10:01 ET Single Cell Sequencing Market worth $3.46 billion by 2030 with 12.2% CAGR | MarketsandMarkets™
driven by its well-established healthcare infrastructure, substantial investments in life sciences research, and the strong presence of leading biotechnology and pharmaceutical companies. The region demonstrates a high adoption rate of single cell sequencing technologies such as scRNAseq and scDNAseq,
More news about: MarketsandMarkets
Aug 25, 2025, 10:00 ET Clongen Laboratories, LLC Announces Launch of Sister Company Clongen Pharma, LLC in March 2026
-- Clongen Laboratories, LLC, a provider of molecular diagnostic services for infectious diseases and a contract research organization for the biotechnology industry, announces plans to launch a sister company, Clongen Pharma, LLC in March 2026. This expansion aims to offer
More news about: Clongen Laboratories, LLC
Aug 25, 2025, 09:13 ET Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. Wainwright 27th
More news about: Anixa Biosciences, Inc.
Aug 25, 2025, 09:00 ET Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 25, 2025, 09:00 ET REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Aug 25, 2025, 08:30 ET AI in Regulatory Medical Writing: Balancing Innovation with Human Expertise, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 25, 2025, 08:30 ET ADC Development: Early On- and Off-Target Testing to Fail Fast, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 25, 2025, 08:05 ET INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
MEETING, Pa., Aug. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Aug 25, 2025, 08:00 ET Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Aug. 25, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that
More news about: Coya Therapeutics
Aug 25, 2025, 08:00 ET Origin Agritech Commences Full-Scale Seed Processing Operations at Xinjiang Production Base
the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
Aug 25, 2025, 08:00 ET ETHZilla announces authorization of $250 million stock repurchase program
top-tier DeFi founders, infrastructure pioneers and other ecosystem heavyweights. The Company, originally formed as an innovative biotechnology company, has also been evolving its business towards software enabled gaming and entertainment. In addition to its ETH treasury strategy
More news about: ETHZilla Corporation
Aug 25, 2025, 06:32 ET Wingor Bio Lands Tens of Millions in Initial Funding with Round Still Open; Forges Ahead on Stem Cell Drug and Clinical Programs
Aug. 25, 2025 /PRNewswire/ -- Shenzhen Wingor Biotechnology Co., Ltd. (hereinafter "Wingor Biotechnology"), a leading Chinese company in stem-cell and gene therapy, is pleased to announce significant progress in a financing
More news about: Wingor
Aug 25, 2025, 06:19 ET Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial
MM in October 2024. About Leads Biolabs Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Leads Biolabs
Aug 25, 2025, 06:00 ET IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
9:10 AM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology AnalystIDEAYA Biosciences 10-Year Anniversary R&D DayMonday, September 8th, 2025
More news about: IDEAYA Biosciences, Inc.
Aug 23, 2025, 10:45 ET Targeted Protein Degradation Market worth $9.85 billion by 2035 with 35.4% CAGR | MarketsandMarkets™
driven by strong R&D infrastructure, robust funding ecosystems, and a favorable regulatory environment. The region is home to several pioneering biotechnology and pharmaceutical companies that are leading the development of TPD platforms, particularly PROTACs and molecular glues. Major players such as
More news about: MarketsandMarkets
Aug 23, 2025, 10:01 ET Biobanking Market worth $11.82 billion by 2030 with 9.1% CAGR | MarketsandMarkets™
By end users, the biobanking services market is segmented into pharmaceutical & biotechnology companies & CROs, and academic & research institutes. The pharmaceutical & biotechnology companies & CROs segment is estimated to register the highest growth rate during the forecast
More news about: MarketsandMarkets